What happened (core claim of the news argument)
The news argument on hepatitis B control supports a “treat-all eligible people” approach instead of narrowly restricting access to therapy. The core claim is that treating eligible patients widely, with timely and appropriate clinical management, can prevent hepatitis B from progressing to severe disease and complications.
Background and earlier position (what the debate contrasts)
The news argument contrasts two policy directions in hepatitis B control: a broad treatment approach for eligible people versus a restrictive approach that limits who can receive therapy. The argument also emphasizes that older adults carry a major share of hepatitis B health burden, and delays in care for eligible patients can worsen outcomes through disease progression.
What changed now (shift in emphasis)
The central shift urged by the argument is not only about which patients should be treated, but also about programme follow-through. The argument calls for consistent policy and clinical delivery so that people who need hepatitis B care actually receive it, and real-world outcomes improve.